News

Denali and Royalty Pharma Secure $275 Million Royalty Agreement

Denali and Royalty Pharma Secure $275 Million Royalty Agreement

Denali Therapeutics and Royalty Pharma Collaborate on Funding Deal

Denali Therapeutics Inc. (NASDAQ: DNLI) and Royalty Pharma plc (NASDAQ: RPRX) have recently announced a significant synthetic royalty funding agreement worth $275 million. This deal is primarily focused on future net sales of the investigational medication tividenofusp alfa. This collaboration aims to advance the treatment opportunities for patients diagnosed with mucopolysaccharidosis type II (MPS II), otherwise known as Hunter syndrome.

About Tividenofusp Alfa

Tividenofusp alfa stands out as Denali's leading enzyme replacement therapy. It's designed specifically to address the symptoms associated with Hunter syndrome, which affects both cognitive and physical abilities. The Biologics License Application for accelerated approval of tividenofusp alfa is currently under the scrutiny of the U.S. Food and Drug Administration (FDA), with a target date for review set for later this year.

What the Leaders Are Saying

Ryan Watts, Ph.D., the Chief Executive Officer of Denali Therapeutics, expressed enthusiasm about this collaboration. He stated, "Partnering with Royalty Pharma really showcases the promising potential of tividenofusp alfa for the Hunter community. These additional funds will enable us to further our development programs as we prepare for the product's launch, which is critically important as we seek solutions for patients suffering from serious diseases.”

Pablo Legorreta, the CEO and Chairman of the Board at Royalty Pharma, echoed these sentiments, expressing delight in the collaboration. He emphasized the innovative nature of tividenofusp alfa, noting its potential to significantly address unmet medical needs in severe cognitive and physical impairments related to Hunter syndrome.

Transaction Details

The transaction includes specific conditions that need to be met, primarily the achievement of accelerated approval from the FDA for tividenofusp alfa. Upon closing the deal, Royalty Pharma is set to provide an initial payment of $200 million. Moreover, an additional payment of $75 million is contingent upon acquiring approval from the European Medicines Agency (EMA) before the end of 2029.

In return for their investment, Royalty Pharma will receive a 9.25% royalty on all worldwide net sales stemming from tividenofusp alfa produced by Denali. The royalty structure is designed to terminate when the payments reach a specified threshold, ensuring a balanced return on investment for both companies.

Advisors Involved

Denali Therapeutics engaged Gibson Dunn as their legal advisor, while Royalty Pharma was supported by Goodwin Procter and Maiwald as their legal counsel. This collaboration of expertise has contributed to a robust framework surrounding the agreement.

Who is Denali Therapeutics?

Denali is a pioneering biotechnology enterprise that focuses on developing biotherapeutics aimed at crossing the blood-brain barrier through its proprietary TransportVehicle platform. The company aspires to deliver effective treatments that transform the lives of individuals coping with neurodegenerative disorders and serious diseases linked to lysosomal storage.

Who is Royalty Pharma?

Founded in 1996, Royalty Pharma is a leader in acquiring biopharmaceutical royalties. They play a crucial role in funding innovation by collaborating with various entities in the biopharmaceutical landscape—from academic institutions to leading pharmaceutical companies. Their extensive portfolio includes both existing royalties from successful medications as well as participations in funding future breakthroughs through clinical trials.

Frequently Asked Questions

What is the focus of the funding agreement between Denali and Royalty Pharma?

The agreement centers on a $275 million royalty funding deal related to tividenofusp alfa, aiming to support its development for treating Hunter syndrome.

What is tividenofusp alfa?

Tividenofusp alfa is an investigational enzyme replacement therapy developed by Denali designed to treat symptoms of mucopolysaccharidosis type II, commonly known as Hunter syndrome.

What are the terms of the transaction?

The deal includes an initial payment of $200 million from Royalty Pharma and an additional $75 million tied to European approval for the treatment.

What is the potential impact of this collaboration?

This partnership can unlock new avenues for addressing serious unmet medical needs in the Hunter community and promote advancements in Denali's development pipeline.

How does Denali's technology work?

Denali utilizes a proprietary TransportVehicle platform designed to enhance the delivery of important therapeutics across the blood-brain barrier, targeting neurodegenerative conditions.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 308

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 350

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 272

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
NatGasHub’s 391% Growth Signals a Real Pipeline Shift

Updated Category News Views 23

Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...

Continue Reading
Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 225

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
3TREES Tests a Bigger Asia-Pacific Growth Blueprint

Updated Category News Views 246

A bucket of paint rarely sounds strategic until it sits inside a regional supply chain. That is the useful part of 3TREES chairman and president Hong Jie's message from the Asia-Pacific Economic Cooperation CEO Summit in Shenzhen on November 17-18, 2026: coatings are not merely a commodity if the supplier can bring materials, energy savings, technical know-how and...

Continue Reading
Lymphatic Research Gains Attention Beyond Wellness Claims

Updated Category News Views 232

Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 377

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 156

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Coloplast A/S Highlights Impressive Full-Year Performance

Updated Category News Views 231

Coloplast A/S Financial Results Overview Coloplast A/S recently announced its full-year financial results for the fiscal year 2023/24, highlighting a solid performance characterized by growth and resilience across various business sectors. Their latest report demonstrates a robust organic growth rate of 8%, coupled with a notable EBIT margin of 27%. In monetary terms, the...

Continue Reading
Introducing Sproutr’s Innovative Program Placement Services

Updated Category News Views 200

Sproutr Unveils Comprehensive Program Placement Services Sproutr, a leading firm in insurance program design and product development, has launched its innovative Program Placement Services. This new offering aims to streamline the entire process of insurance program development, ensuring that it aligns well from the initial design to the final placement with carriers. The...

Continue Reading
Unstoppable Domains Introduces .DEMOS: Redefining Digital Identity

Updated Category News Views 147

Introducing .DEMOS: A New Era of Digital Identity In an exciting development, Unstoppable Domains has rolled out a new top-level domain, .DEMOS, in collaboration with Kynesys.xyz. This innovative domain is positioned as a Web3-first solution designed to foster connection and collaboration in a borderless internet landscape. The name .DEMOS is derived from the Greek term...

Continue Reading
Investors Urged to Join Class Action Against Open Lending Corporation

Updated Category News Views 193

Open Lending Corporation: A Call to Action for Affected Investors Investors suffering heavy losses in Open Lending Corporation (NASDAQ: LPRO) are presented with the chance to take action. It's an opportunity for those impacted by the recent financial discrepancies and corporate disclosures to become lead plaintiffs in a class action lawsuit. Class Action Lawsuit Details...

Continue Reading
McAfee Revolutionizes Digital Security with AI Techniques

Updated Category News Views 253

Innovative Protection: McAfee Leads in AI-Powered Security Recognized as a leader in online security, McAfee has become synonymous with consumer safety in a rapidly evolving digital landscape. With the escalation of online threats, including sophisticated deepfakes and scams, McAfee's advanced artificial intelligence capabilities make it the prime choice for individuals...

Continue Reading